12 Month Price Forecast For CVAC
Distance to CVAC Price Forecasts
CVAC Price Momentum
๐ค Considering CureVac (CVAC)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 8, 2025 9:57 AM UTC
CVAC Analyst Ratings & Price Targets
Based on our analysis of 7 Wall Street analysts, CVAC has a consensus that is bullish. The median price target is $4.91, with forecasts ranging from $2.44 to $15.63. Currently, there are 4 Buy ratings, 2 Hold ratings, and 1 Sell ratings.
With CVAC currently trading at $3.58, the median price forecast suggests a 37.1% upside. The most optimistic forecast comes from at , projecting a 336.6% upside, while at provides the most conservative target, suggesting a -31.9% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CVAC Analyst Consensus
CVAC Price Target Range
Latest CVAC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CVAC.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Sep 16, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $16.00 |
Aug 16, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $16.00 |
Jul 3, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $18.00 |
Apr 25, 2024 | Leerink Partners | Mani Foroohar | Market Perform | Downgrade | $4.00 |
Apr 5, 2024 | Guggenheim | Evan Wang | Neutral | Reiterates | $0.00 |
Aug 21, 2023 | B of A Securities | Geoff Meacham | Underperform | Maintains | $8.00 |
Jun 8, 2023 | SVB Securities | Mani Foroohar | Outperform | Initiates | $13.00 |
Apr 26, 2023 | JMP Securities | Roy Buchanan | Outperform | Maintains | $24.00 |
Jan 19, 2023 | UBS | Eliana Merle | Buy | Upgrade | $18.00 |
Jan 9, 2023 | Jefferies | Eun Yang | Buy | Upgrade | $0.00 |
Nov 17, 2022 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $34.00 |
Apr 22, 2022 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $37.00 |
Jan 21, 2022 | B of A Securities | Geoff Meacham | Underperform | Downgrade | $20.00 |
Dec 31, 2021 | Deutsche Bank | Hold | Initiates | $0.00 | |
Oct 22, 2021 | Deutsche Bank | Hold | Initiates | $0.00 | |
Jun 17, 2021 | B of A Securities | Neutral | Downgrade | $0.00 | |
Apr 26, 2021 | Guggenheim | Buy | Initiates | $0.00 | |
Dec 10, 2020 | Credit Suisse | Underperform | Downgrade | $0.00 | |
Sep 8, 2020 | B of A Securities | Buy | Initiates | $0.00 | |
Sep 8, 2020 | Jefferies | Hold | Initiates | $0.00 |
Stocks Similar to CureVac NV
The following stocks are similar to CureVac based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CureVac NV (CVAC) Financial Data
CureVac NV has a market capitalization of $805.37M with a P/E ratio of 7.3x. The company generates $68.00M in trailing twelve-month revenue with a -131.3% profit margin.
Revenue growth is +90.5% quarter-over-quarter, while maintaining an operating margin of -493.6% and return on equity of -54.3%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

CureVac NV (CVAC) Company Overview
About CureVac NV
Develops transformative mRNA-based medicines.
CureVac N.V. focuses on developing innovative mRNA-based therapies and vaccines. The company generates revenue through the advancement of its drug candidates into clinical trials, aiming for eventual commercialization and partnerships with other pharmaceutical companies.
Founded in 2000 and headquartered in Tรผbingen, Germany, CureVac is actively working on several vaccine candidates targeting diseases like COVID-19 and rabies, as well as cancer treatments. The company's work in mRNA technology positions it strategically within the biopharmaceutical industry, which is seeing increased interest and investment in mRNA therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
999
CEO
Dr. Alexander Zehnder M.B.A., M.D.
Country
Germany
IPO Year
2020
Website
www.curevac.comCureVac NV (CVAC) Latest News & Analysis
CureVac's CVGBM vaccine showed positive safety and immunogenicity in phase 1 for glioblastoma. Key milestones include data in 2025 and a phase 2 study in 2026. They are also advancing a vaccine for NSCLC.
CureVac's positive vaccine data and upcoming key study milestones could enhance its market position and attractiveness, potentially boosting stock value and investor interest.
2 Small-Cap Stocks Set to Shine in a Bull Market
1 month agoSmall-cap stocks tend to perform well in bullish markets due to their growth potential and sensitivity to improving economic conditions, attracting investor confidence and capital.
Small-cap stocks may lead market gains in bullish conditions, attracting risk-seeking investors, which can boost overall market performance and influence portfolio allocations.
CureVac (CVAC) stock is experiencing notable activity in the options market, signaling that investors should monitor it closely.
Increased activity in CureVac's options market signals potential volatility or significant price movement, which could impact stock performance and investment strategies.
CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript
2 months agoCureVac N.V. will hold its Q3 2024 earnings conference call on November 12, 2024, at 9:00 AM ET, featuring key executives and analysts from major financial institutions.
CureVac's Q3 earnings call will provide crucial insights into its financial performance and strategic direction, impacting stock valuation and investor sentiment.
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
2 months agoCureVac reported a โฌ400M upfront payment from GSK, raising cash to โฌ551M, extending runway to 2028. Positive trial results in glioblastoma and influenza, new cancer program initiated, and workforce cut planned.
The substantial cash increase and pipeline advancements signal strong financial health, operational efficiency, and growth potential, positively influencing investor confidence and stock performance.
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024
3 months agoCureVac N.V. will release its Q3 and 2024 year-to-date financial results and business updates on November 12, 2024.
CureVac's upcoming financial report may impact its stock performance, providing insights into its mRNA developments and overall market position, influencing investor sentiment and decisions.
Frequently Asked Questions About CVAC Stock
What is CureVac NV's (CVAC) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, CureVac NV (CVAC) has a median price target of $4.91. The highest price target is $15.63 and the lowest is $2.44.
Is CVAC stock a good investment in 2025?
According to current analyst ratings, CVAC has 4 Buy ratings, 2 Hold ratings, and 1 Sell ratings. The stock is currently trading at $3.58. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for CVAC stock?
Wall Street analysts predict CVAC stock could reach $4.91 in the next 12 months. This represents a 37.1% increase from the current price of $3.58. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is CureVac NV's business model?
CureVac N.V. focuses on developing innovative mRNA-based therapies and vaccines. The company generates revenue through the advancement of its drug candidates into clinical trials, aiming for eventual commercialization and partnerships with other pharmaceutical companies.
What is the highest forecasted price for CVAC CureVac NV?
The highest price target for CVAC is $15.63 from at , which represents a 336.6% increase from the current price of $3.58.
What is the lowest forecasted price for CVAC CureVac NV?
The lowest price target for CVAC is $2.44 from at , which represents a -31.9% decrease from the current price of $3.58.
What is the overall CVAC consensus from analysts for CureVac NV?
The overall analyst consensus for CVAC is bullish. Out of 7 Wall Street analysts, 4 rate it as Buy, 2 as Hold, and 1 as Sell, with a median price target of $4.91.
How accurate are CVAC stock price projections?
Stock price projections, including those for CureVac NV, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.